Clover Health Investments earnings shift draws investor focus

Clover Health Investments (CLOV) is back on investor radars after reporting a second quarter net income of US$28 million, compared with a net loss a year earlier, and issuing higher full year 2026 revenue and profit guidance.

Clover Health Investments’ latest results and raised 2026 guidance have come alongside a strong shift in sentiment, with a 90.87% year to date share price return and a 76.25% total shareholder return over one year. This points to building momentum from a lower base over the past five years.

If this kind of re-rating story interests you, it can be worth scanning other companies that might be earlier in a similar cycle using the Simply Wall St screener for 42 healthcare AI stocks

The recent swing back to profitability and sharp share price move has already reset expectations for Clover Health Investments. The key issue now is whether the current valuation still leaves meaningful upside or if most of the easy gains are behind it.

Most Popular Narrative: 11% Undervalued

The most followed narrative currently places Clover Health Investments’ fair value at $5.17 per share, compared with a last close of $4.60. This frames the recent rally against the remaining upside implied by that model.

The analysts have a consensus price target of $5.17 for Clover Health Investments based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.2 billion, earnings will come to $73.3 million, and it would be trading on a PE ratio of 51.4x, assuming you use a discount rate of 7.2%.

Want to see what sits behind that valuation gap? The narrative leans on faster revenue expansion, margin lift and a premium earnings multiple. The exact path is where it gets interesting.

Result: Fair Value of $5.17 (UNDERVALUED)

However, there are still clear pressure points for Clover Health Investments, including rising medical and pharmacy costs, as well as ongoing regulatory and legal scrutiny related to its Medicare operations.

Next Steps

With both risks and rewards in focus for Clover Health Investments, it helps to move quickly and test the story against your own expectations. To see how those trade offs stack up in one place, review the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Clover Health Investments?

If you are serious about building a stronger portfolio, do not stop with Clover Health Investments. Use the Simply Wall St screener to uncover fresh stock ideas that fit your goals.

• Target potential mispricings by scanning a curated list of companies trading below estimated worth through the 52 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with higher yields using the 10 dividend fortresses.
• Prioritise resilience by zeroing in on companies screened for financial robustness using the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.